Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing.
A topical microbicide that women can use to prevent sexually transmitted diseases (STDs) is essential, and many microbicide candidates are being tested for activity against human immunodeficiency virus and other STDs, including Chlamydia trachomatis. Screening assays for assessing the activity of microbicides against C. trachomatis are typically done with laboratory-adapted strains, but it is possible that recent clinical isolates may have different susceptibilities to microbicides, as has been seen with Neisseria gonorrhoeae and Lactobacillus spp. (B. J. Moncla and S. L. Hillier, Sex. Transm. Dis. 32:491-494, 2005). We utilized three types of microbicides to help define this aspect of our assay to test microbicides against C. trachomatis in vitro. To simulate conditions of transmission, we used an assay that we previously developed in which we exposed chlamydial elementary bodies to microbicides prior to contact with epithelial cells. We first determined the toxicity of microbicides to the cells used to culture Chlamydia trachomatis in the assay and, if necessary, modified the assay to eliminate toxicity at the concentrations tested. We compared the sensitivities of recent clinical isolates of Chlamydia trachomatis versus laboratory strains of the same serovar and found major differences in sensitivity to nonoxynol-9 (non-9), but only minor differences were seen with the other microbicides. We thus conclude that when assessing activity of potential topical microbicides versus the obligate intracellular bacteria C. trachomatis, the use of recent clinical isolates may not be necessary to draw a conclusion about a microbicide's effectiveness. However, it is important to keep in mind that differences (like those seen with non-9) are possible and that clinical isolates could be included in later stages of testing.
Skinner
M C
MC
Department of Medicine, Division of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.
Stamm
W E
WE
Lampe
M L
ML
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D002692:Chlamydia trachomatis / Q000187:drug effects*; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D017137:Nonoxynol / Q000494:pharmacology; D010078:Oxazines; D010400:Penicillin G / Q000494:pharmacology; D011112:Polymyxin B / Q000494:pharmacology; D014966:Xanthenes
D000890:Anti-Infective Agents; D010078:Oxazines; D014966:Xanthenes; C005843:resazurin; D017137:Nonoxynol; D011112:Polymyxin B; D010400:Penicillin G